Company profile: Bolder BioPath
1.1 - Company Overview
Company description
- Provider of pharmacology and pathology services.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Bolder BioPath
Optimer Pharmaceuticals
HQ: United States
Website
- Description: Provider of anti-infective biopharmaceutical products focused on discovering, developing and commercializing treatments for gastrointestinal infections, including late-stage candidates fidaxomicin and Pruvel (prulifloxacin).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Optimer Pharmaceuticals company profile →
ApiJect
HQ: United States
Website
- Description: Provider of a medical technology platform enabling scalable manufacturing and fill-finish of prefilled, single-dose injectors using Blow-Fill-Seal aseptic packaging. Offers the Prefilled ApiJect Injector with a pen needle–style hub; technology licensing for BFS mold/device design, development and production support; and design and engineering services for BFS fill-finish of temperature-sensitive biologics and vaccines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ApiJect company profile →
TD2
HQ: United States
Website
- Description: Provider of oncology-focused contract research services, offering data-driven clinical study management for Phase I–III trials; preclinical tools with 400+ cancer models to maximize data value and predict patient response; regulatory support (IND readiness, development, filings, FDA interactions); PK/ADME assays; and CDX models including NCI-H1963 (lung) and CCRF-CEM (T-ALL) to accelerate translational oncology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TD2 company profile →
Capacity Bio
HQ: United States
Website
- Description: Provider of mitophagy-focused therapeutics and a development platform to restore mitochondrial quality control in disease. Offers mitophagy agonists (small molecules, peptides, nanoparticles) to enhance removal of dysfunctional mitochondria; mitochondrial modulators in preclinical programs for mitochondrial dysfunction across various diseases; and a mitophagy therapeutic platform to induce mitochondrial turnover and improve mitochondrial performance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Capacity Bio company profile →
Evotec
HQ: Germany
Website
- Description: Provider of drug discovery and gene therapy solutions, delivering CRO/CDMO services from initial research to clinical trials; AI-powered PanOmics and iPSC technologies for disease understanding in small molecules and biotherapeutics; hit identification; J.POD continuous biomanufacturing for biologics; and a proprietary ion channel assay.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Evotec company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Bolder BioPath
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Bolder BioPath
2.2 - Growth funds investing in similar companies to Bolder BioPath
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Bolder BioPath
4.2 - Public trading comparable groups for Bolder BioPath
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →